{"id":390722,"date":"2018-03-26T00:00:00","date_gmt":"2018-03-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2018\/"},"modified":"2026-05-01T23:41:15","modified_gmt":"2026-05-01T23:41:15","slug":"algoim0042-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0042-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-adult-us-2018\/","title":{"rendered":"Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2018"},"content":{"rendered":"<p>The primary goal of ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s, corticosteroids) are typically used to treat mild to moderate patients, whereas <abbr title=\"intravenous\">IV<\/abbr> and subcutaneous <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are primarily reserved for moderate to severe patients refractory to conventional treatment or for first-line treatment in the most severe patients. Lack of primary response or loss of response to <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors is an ongoing concern; however, the <abbr title=\"intravenous\">IV<\/abbr>-delivered <abbr title=\"cell adhesion molecule\">CAM<\/abbr> inhibitor Entyvio (Takeda) is a recent entry to the treatment armamentarium that offers an alternative mechanism of action for these patients, and has led to increasing competition among the biologics.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"ulcerative colitis\">UC<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"ulcerative colitis\">UC<\/abbr> patients?<\/li>\n<li>How has Entyvio been integrated into the treatment algorithm?<\/li>\n<li>\u00a0What proportion of <abbr title=\"ulcerative colitis\">UC<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>\u00a0What percentage of <abbr title=\"ulcerative colitis\">UC<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis <\/em>provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390722","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390722\/revisions"}],"predecessor-version":[{"id":393846,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390722\/revisions\/393846"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}